Checkmate Pharmaceuticals Inc. (CMPI)
$10.50
$0.00 (0.00%)As on 09-Jun-2022 09:30EDT
Market cap
$231 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
4.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-63 Mln
-
ROE
-0.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-2.9
-
Face value
--
-
Shares outstanding
22,038,200
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Checkmate Pharmaceuticals (CMPI)
| 265.9 | 1.2 | 228.1 | 55.8 | -- | -- | -- |
|
BSE Sensex*
| -11.2 | -4.2 | -10.2 | -8.7 | 7.0 | 8.4 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
|---|---|
|
Checkmate Pharmaceuticals (CMPI)
| -80.3 |
|
S&P Small-Cap 600
| 25.3 |
|
BSE Sensex
| 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Checkmate Pharmaceuticals (CMPI)
|
10.5 | 231.4 | 0.0 | -63.1 | -- | -92.5 | -- | 4.2 |
| 94.9 | 27,915.8 | 5,806.9 | 589.5 | 12.6 | 15.2 | 48.1 | 7.1 |
Shareholding Pattern
View DetailsAbout Checkmate Pharmaceuticals (CMPI)
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with... pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. As of May 27, 2022, Checkmate Pharmaceuticals, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc. Read more
-
CFO & Principal Accounting Officer
Mr. Robert F. Dolski
-
CFO & Principal Accounting Officer
Mr. Robert F. Dolski
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Checkmate Pharmaceuticals (CMPI)
What is the current share price of Checkmate Pharmaceuticals Inc (CMPI) Today?
The share price of Checkmate Pharmaceuticals Inc (CMPI) is $10.50 (NASDAQ) as of 09-Jun-2022 09:30 EDT. Checkmate Pharmaceuticals Inc (CMPI) has given a return of 55.79% in the last 1 years.
What is the current PB & PE ratio of Checkmate Pharmaceuticals Inc (CMPI)?
Since, TTM earnings of Checkmate Pharmaceuticals Inc (CMPI) is negative, P/E ratio is not available.
The P/B ratio of Checkmate Pharmaceuticals Inc (CMPI) is 4.19 times as on 09-Jun-2022, a 1 discount to its peers’ median range of 4.25 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
-1.03
|
0.91
|
|
2020
|
-3.95
|
1.17
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2021
|
-1.03
|
0.91
|
What is the 52 Week High and Low of Checkmate Pharmaceuticals Inc (CMPI)?
The 52-week high and low of Checkmate Pharmaceuticals Inc (CMPI) are Rs -- and Rs -- as of 19-May-2026.
What is the market cap of Checkmate Pharmaceuticals Inc (CMPI)?
Checkmate Pharmaceuticals Inc (CMPI) has a market capitalisation of $ 231 Mln as on 09-Jun-2022. As per SEBI classification, it is a Small Cap company.
Should I invest in Checkmate Pharmaceuticals Inc (CMPI)?
Before investing in Checkmate Pharmaceuticals Inc (CMPI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.